Corixa Garners Manufacturing Facility For Pvac Through Merger With Ribi
Executive Summary
Corixa may produce its Pvac immunotherapeutic at Ribi's Hamiliton, Mont. facility following the companies' merger.
You may also be interested in...
Corixa Acquisition Of Coulter Gives Company Bexxar, Pending At FDA
Corixa's acquisition of Coulter will give the company its most advanced late-stage clinical product, the non-Hodgkin's lymphoma therapy Bexxar.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011